BRPI0906351A2 - uso de agonistas hedgehog no tratamento de distúrbios relacionados ao musculoesquelético - Google Patents

uso de agonistas hedgehog no tratamento de distúrbios relacionados ao musculoesquelético

Info

Publication number
BRPI0906351A2
BRPI0906351A2 BRPI0906351A BRPI0906351A BRPI0906351A2 BR PI0906351 A2 BRPI0906351 A2 BR PI0906351A2 BR PI0906351 A BRPI0906351 A BR PI0906351A BR PI0906351 A BRPI0906351 A BR PI0906351A BR PI0906351 A2 BRPI0906351 A2 BR PI0906351A2
Authority
BR
Brazil
Prior art keywords
treatment
musculoskeletal disorders
hedgehog agonists
hedgehog
agonists
Prior art date
Application number
BRPI0906351A
Other languages
English (en)
Inventor
Donald Armstrong Dustin
Kadam Shilpa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0906351A2 publication Critical patent/BRPI0906351A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0906351A 2008-01-29 2009-01-27 uso de agonistas hedgehog no tratamento de distúrbios relacionados ao musculoesquelético BRPI0906351A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2442308P 2008-01-29 2008-01-29
PCT/EP2009/050868 WO2009095378A1 (en) 2008-01-29 2009-01-27 Use of hedgehog agonists in the treatment of musculoskeletal-related disorders

Publications (1)

Publication Number Publication Date
BRPI0906351A2 true BRPI0906351A2 (pt) 2019-09-24

Family

ID=40459640

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906351A BRPI0906351A2 (pt) 2008-01-29 2009-01-27 uso de agonistas hedgehog no tratamento de distúrbios relacionados ao musculoesquelético

Country Status (11)

Country Link
US (1) US20100317699A1 (pt)
EP (1) EP2247288A1 (pt)
JP (1) JP2011510947A (pt)
KR (1) KR20100116177A (pt)
CN (1) CN101932313A (pt)
AU (1) AU2009209702A1 (pt)
BR (1) BRPI0906351A2 (pt)
CA (1) CA2713376A1 (pt)
EA (1) EA201001203A1 (pt)
MX (1) MX2010008207A (pt)
WO (1) WO2009095378A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011102908A2 (en) * 2010-02-22 2011-08-25 Duke University Biomarkers of musculoskeletal disease
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
US10557124B2 (en) * 2015-04-22 2020-02-11 The Regents Of The University Of Michigan Compositions and methods for obtaining stem cell derived lung tissue, and related uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2302780A1 (en) * 1997-08-29 1999-03-04 Ontogeny, Inc. Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2001074344A2 (en) * 2000-03-30 2001-10-11 Curis, Inc. Small organic molecule regulators of cell proliferation

Also Published As

Publication number Publication date
EA201001203A1 (ru) 2011-04-29
AU2009209702A1 (en) 2009-08-06
MX2010008207A (es) 2012-10-01
KR20100116177A (ko) 2010-10-29
WO2009095378A1 (en) 2009-08-06
JP2011510947A (ja) 2011-04-07
EP2247288A1 (en) 2010-11-10
US20100317699A1 (en) 2010-12-16
CA2713376A1 (en) 2009-08-06
CN101932313A (zh) 2010-12-29

Similar Documents

Publication Publication Date Title
LTC2340031I2 (lt) Gdf gaudyklės, skirtos naudoti anemijos gydymui
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
BRPI0818144A2 (pt) Produção de termolisin e variantes deste, e uso em detergentes líquidos
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
SI2350096T1 (sl) Postopki za zdravljenje hepatične encefalopatije
CO6751293A2 (es) Derivados heterocíclicos novedosos y su uso en e tratamiento de trastornos neurológicos
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
PL2468290T3 (pl) Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
BRPI1005292A2 (pt) composição de decapagem e uso da composição
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
PL2200600T3 (pl) Nerameksan do zastosowania w leczeniu podostrego szumu usznego
BRPI0920334A2 (pt) métodos para o tratamento de distúrbios pulmonares com formulações de amicacina lipossomal.
BR112012001344A2 (pt) derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
BRPI0810475A2 (pt) uso de dimiracetam no tratamento de dor crônica
DK2323644T3 (da) N-substituerede benzenpropanamid- eller benzenpropenamidderivater til anvendelse ved behandlingen af smerte
BRPI0915905A2 (pt) uso de derivados de pirimidilaminobenzamida para o tratamento de fibrose
BRPI0907956A2 (pt) Uso de ranolazina para o tratamento de doenças cardiovasculares
BRPI0821026A2 (pt) Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
BRPI0909840A2 (pt) Uso de 4-tio-2-deoxinucleosídios
EP2199352A4 (en) AQUEOUS SURFACE TREATMENT

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.